Developer docs
API playgroundTry for free, no card

Search company profiles

Scienta Lab

Full company profile

uuid0000xor

Namestring
Scienta Lab
Legal namestring
Scienta Lab
Websiteurl
scientalab.com
Company typeenum
Private
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, precision immunology, foundation model, translational research, immuno-inflammatory diseases
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI drug discovery software
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Customized Commercial Applications
TypeSubscription Recurring
Description

The company offers customized commercial applications of EVA through partnerships with biopharmaceutical companies, providing tailored solutions for specific drug development programs.

scientalab.com
2Open Model Access
TypeFreemium
Description

An open version of the transcriptomic model is released for researchers at no cost, creating community adoption and potential pathway to commercial upsell.

scientalab.com
3Partnership-based Licensing
TypeLicensing Royalties
Description

Customized commercial applications through partnerships with biopharmaceutical companies for drug discovery and development programs.

pharmiweb.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1EVA
Description

Multimodal AI foundation model for immunology and inflammation drug discovery, trained on 500K+ transcriptomics samples and 20M histology tiles.

scientalab.com
+1 more record
Core offering1 text field

Scienta Lab builds and sells EVA, a 440M-parameter cross-species, multimodal AI foundation model purpose-built for immunology and inflammation drug discovery. EVA integrates transcriptomics and histology data to predict clinical trial success, support target prioritization, enable preclinical-to-human translation, and optimize patient stratification for biopharmaceutical R&D teams. The company delivers EVA as customized commercial applications through partnerships with biopharma companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Up to 2x performance gains compared to current industry standards across 40 benchmarked use cases
+3 more records
Product overview1 text field

Scienta Lab provides EVA, a foundation model for immunology and inflammation drug discovery, powered by ImmunAtlas, their proprietary training dataset. EVA integrates over 500K transcriptomic samples and 20M histology tiles across human and mouse to predict clinical outcomes throughout the drug development pipeline. The platform addresses three key stages: target and mechanism prioritization (ranking programs by predicted clinical success probability), preclinical-to-human translation (predicting clinical efficacy from preclinical data), and patient stratification for trial optimization. EVA is offered as a commercial product via partnerships with biopharmaceutical teams, with an open transcriptomic version available for researchers.

Product and service1 record
1EVA
CategoryAI foundation model / drug discovery software
Description

EVA is a 440M-parameter cross-species, multimodal foundation model for immunology and inflammation drug discovery. It integrates transcriptomics (500K+ samples) and histology (20M+ tiles) from human and mouse, predicting clinical trial success, translational risk, and patient response to support target prioritization, preclinical-to-human translation, and trial optimization. Sold to biopharmaceutical R&D teams via customized commercial partnerships.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2025-04-09
Description

Partnership to advance multimodal and explainable AI research in collaboration with DataIA-Cluster, supporting Scienta Lab's development of foundation models for immunology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-29
Description

Strategic partnership to leverage artificial intelligence in precision immunotherapy. The collaboration aims to advance the understanding of underlying immune pathways causing immune-mediated and inflammatory diseases, potentially leading to more personalised treatments that improve patient health and quality of life.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Isomorphic Labs
TypeBroad incumbent
Description

Isomorphic Labs is Alphabet's commercial drug discovery arm built on DeepMind's AlphaFold and related biology foundation models. It is a broad incumbent that competes with Scienta Lab at the foundation-model-for-drug-discovery layer but operates across all therapeutic areas rather than specializing in immunology.

TypeBroad incumbent
Description

Schrödinger provides physics-based and AI-driven molecular simulation software for drug discovery across pharma and biotech. It is a broad incumbent because it offers overlapping computational discovery capabilities, but operates as a horizontal software platform rather than focusing on immuno-inflammation patient-level prediction.

TypeDirect peer
Description

Recursion builds AI foundation models across high-content biology and chemistry data to discover and develop new therapeutics. It is a direct peer because both companies train large-scale foundation models on proprietary multi-omic and imaging data to predict drug efficacy and prioritize targets.

TypeEmerging player
Description

EvolutionaryScale develops large-scale AI foundation models for biology, including protein language and genomic models for research and pharma partners. It is an emerging player that competes in the same foundation-model-for-biology category as EVA, but with a broader biology focus rather than immunology specialization.

TypeDirect peer
Description

BenevolentAI builds AI foundation models on biomedical knowledge graphs and multi-omic data to identify novel targets, with an explicit focus on immunology and inflammation. It is a direct peer because both companies target immuno-inflammatory target prioritization and translational decision support.

TypeDirect peer
Description

Iktos is a French AI company applying generative models to small-molecule and macrocyclic drug design for pharma partners. It is a direct peer because it is a fellow French AI-for-drug-discovery vendor selling enterprise partnerships to biopharma, often on multi-year collaboration structures.

TypeDirect peer
Description

Owkin is a French AI-for-biopharma company applying multimodal AI to patient data for drug discovery and clinical research, with strong ties to European hospitals and pharma. It is a direct peer to Scienta Lab because both are European AI biotechs using multimodal biology data to support pharma R&D decisions.

TypeDirect peer
Description

Generate Biomedicines builds generative AI foundation models for protein and biologic design, partnering with pharma on novel therapeutics. It is a direct peer because both companies pair proprietary training datasets with foundation-model architectures to predict therapeutic behavior and partner with biopharma on drug programs.

TypeDirect peer
Description

Exscientia applies AI to accelerate small-molecule drug discovery and has expanded into patient-derived translational models. It is a direct peer because it sells AI-driven drug discovery and translational risk reduction to biopharma, overlapping with Scienta Lab's translational and clinical-trial optimization value proposition.

TypeDirect peer
Description

Insitro is a US-based AI drug discovery company building machine learning models on patient-derived data to predict clinical outcomes. It is a direct peer because both companies build foundation/AI models on multi-omic and clinical data to derisk pharma pipelines, with similar target prioritization and translational use cases.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Scienta Lab

AI drug discovery softwarescientalab.com

Scienta Lab firmographics

Firmographics
Name
Scienta Lab
Legal name
Scienta Lab
Website
https://scientalab.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Scienta Lab industry classification

Industry
Product category
AI drug discovery software
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • AI drug discovery
  • Precision immunology
  • Foundation model
  • Translational research
  • Immuno-inflammatory diseases

Where Scienta Lab is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Scienta Lab business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Customized Commercial Applications: The company offers customized commercial applications of EVA through partnerships with biopharmaceutical companies, providing tailored solutions for specific drug development programs.
  2. Open Model Access: An open version of the transcriptomic model is released for researchers at no cost, creating community adoption and potential pathway to commercial upsell.
  3. Partnership-based Licensing: Customized commercial applications through partnerships with biopharmaceutical companies for drug discovery and development programs.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Scienta Lab product offering

Product offering

Core offering

Scienta Lab builds and sells EVA, a 440M-parameter cross-species, multimodal AI foundation model purpose-built for immunology and inflammation drug discovery. EVA integrates transcriptomics and histology data to predict clinical trial success, support target prioritization, enable preclinical-to-human translation, and optimize patient stratification for biopharmaceutical R&D teams. The company delivers EVA as customized commercial applications through partnerships with biopharma companies.

Product overview

Scienta Lab provides EVA, a foundation model for immunology and inflammation drug discovery, powered by ImmunAtlas, their proprietary training dataset. EVA integrates over 500K transcriptomic samples and 20M histology tiles across human and mouse to predict clinical outcomes throughout the drug development pipeline. The platform addresses three key stages: target and mechanism prioritization (ranking programs by predicted clinical success probability), preclinical-to-human translation (predicting clinical efficacy from preclinical data), and patient stratification for trial optimization. EVA is offered as a commercial product via partnerships with biopharmaceutical teams, with an open transcriptomic version available for researchers.

Differentiator

Problem solved

Functional benefit

Brands

  • EVA: Multimodal AI foundation model for immunology and inflammation drug discovery, trained on 500K+ transcriptomics samples and 20M histology tiles.
  • ImmunAtlas

Products and services

  • EVA EVA is a 440M-parameter cross-species, multimodal foundation model for immunology and inflammation drug discovery. It integrates transcriptomics (500K+ samples) and histology (20M+ tiles) from human and mouse, predicting clinical trial success, translational risk, and patient response to support target prioritization, preclinical-to-human translation, and trial optimization. Sold to biopharmaceutical R&D teams via customized commercial partnerships.

Quantifiable outcome

  • Up to 2x performance gains compared to current industry standards across 40 benchmarked use cases
  • +3 more outcomes

Companies that use Scienta Lab

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Scienta Lab technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Scienta Lab partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered supporting and core.

  • DataIA-ClustersupportingTechnology or Integration · 9 April 2025Partnership to advance multimodal and explainable AI research in collaboration with DataIA-Cluster, supporting Scienta Lab's development of foundation models for immunology.
  • OSE ImmunotherapeuticscoreStrategic or Co-development Partner · 29 January 2025Strategic partnership to leverage artificial intelligence in precision immunotherapy. The collaboration aims to advance the understanding of underlying immune pathways causing immune-mediated and inflammatory diseases, potentially leading to more personalised treatments that improve patient health and quality of life.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Scienta Lab competitors and assessment

Company assessment

Broad incumbents

  • Isomorphic Labs: Isomorphic Labs is Alphabet's commercial drug discovery arm built on DeepMind's AlphaFold and related biology foundation models. It is a broad incumbent that competes with Scienta Lab at the foundation-model-for-drug-discovery layer but operates across all therapeutic areas rather than specializing in immunology.
  • Schrödinger: Schrödinger provides physics-based and AI-driven molecular simulation software for drug discovery across pharma and biotech. It is a broad incumbent because it offers overlapping computational discovery capabilities, but operates as a horizontal software platform rather than focusing on immuno-inflammation patient-level prediction.

Direct peers

  • Recursion Pharmaceuticals: Recursion builds AI foundation models across high-content biology and chemistry data to discover and develop new therapeutics. It is a direct peer because both companies train large-scale foundation models on proprietary multi-omic and imaging data to predict drug efficacy and prioritize targets.
  • BenevolentAI: BenevolentAI builds AI foundation models on biomedical knowledge graphs and multi-omic data to identify novel targets, with an explicit focus on immunology and inflammation. It is a direct peer because both companies target immuno-inflammatory target prioritization and translational decision support.
  • Iktos: Iktos is a French AI company applying generative models to small-molecule and macrocyclic drug design for pharma partners. It is a direct peer because it is a fellow French AI-for-drug-discovery vendor selling enterprise partnerships to biopharma, often on multi-year collaboration structures.
  • Owkin: Owkin is a French AI-for-biopharma company applying multimodal AI to patient data for drug discovery and clinical research, with strong ties to European hospitals and pharma. It is a direct peer to Scienta Lab because both are European AI biotechs using multimodal biology data to support pharma R&D decisions.
  • Generate Biomedicines: Generate Biomedicines builds generative AI foundation models for protein and biologic design, partnering with pharma on novel therapeutics. It is a direct peer because both companies pair proprietary training datasets with foundation-model architectures to predict therapeutic behavior and partner with biopharma on drug programs.
  • Exscientia: Exscientia applies AI to accelerate small-molecule drug discovery and has expanded into patient-derived translational models. It is a direct peer because it sells AI-driven drug discovery and translational risk reduction to biopharma, overlapping with Scienta Lab's translational and clinical-trial optimization value proposition.
  • Insitro: Insitro is a US-based AI drug discovery company building machine learning models on patient-derived data to predict clinical outcomes. It is a direct peer because both companies build foundation/AI models on multi-omic and clinical data to derisk pharma pipelines, with similar target prioritization and translational use cases.

Emerging players

  • EvolutionaryScale: EvolutionaryScale develops large-scale AI foundation models for biology, including protein language and genomic models for research and pharma partners. It is an emerging player that competes in the same foundation-model-for-biology category as EVA, but with a broader biology focus rather than immunology specialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Scienta Lab social profiles

Digital presence

Scienta Lab compliance and trust

Trust signal

Compliance1 record

Scienta Lab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Scienta Lab leadership team

Management profile

Number of profiles

Profiles6 records

Scienta Lab funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Scienta Lab M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scienta Lab

What does Scienta Lab do?

Scienta Lab builds and sells EVA, a 440M-parameter cross-species, multimodal AI foundation model purpose-built for immunology and inflammation drug discovery. EVA integrates transcriptomics and histology data to predict clinical trial success, support target prioritization, enable preclinical-to-human translation, and optimize patient stratification for biopharmaceutical R&D teams. The company delivers EVA as customized commercial applications through partnerships with biopharma companies.

Is Scienta Lab a public or private company?

Scienta Lab is a private company. It is classified as venture growth investor backed and is currently operating.

When was Scienta Lab founded?

Scienta Lab was founded in 2021. It employs 11 to 50 people.

Where is Scienta Lab based?

Scienta Lab is headquartered in Paris, France, in the Europe region.

How does Scienta Lab make money?

Three revenue lines are on record. Customized Commercial Applications are the primary driver. The others are open Model Access and partnership-based Licensing.

Who are Scienta Lab's main competitors?

Broad incumbents on record are Isomorphic Labs and Schrödinger. Direct peers are Recursion Pharmaceuticals, BenevolentAI, Iktos, Owkin, Generate Biomedicines, Exscientia and Insitro. EvolutionaryScale is listed as an emerging player.

Does Scienta Lab have an API?

No public API is recorded for Scienta Lab.

What industry is Scienta Lab in?

Scienta Lab's product category is AI drug discovery software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Silicon RepublicThe deep-tech founder using AI to address immunology challengesCamille Bouget, CEO and co-founder of biotechnology start-up Scienta Lab, founded in 2021, discusses how the company's multimodal AI model EVA is being applied across the immunology drug development pipeline to identify therapeutic targets, evaluate preclinical biological signals, and match patients to trials. The article highlights the broader challenge of high late-stage attrition in immunology research, where programmes frequently fail at phase II or III after years of investment, and emphasizes that multidisciplinary teams combining immunology, bioinformatics, machine learning, and clinical pharmacology are critical to building biologically meaningful AI models.Longevity.TechnologyScienta’s new AI model targets aging-linked inflammationScienta Lab, a Paris-based deeptech startup, has launched EVA, a multimodal AI model designed to accelerate drug discovery in immunology and inflammation by harmonizing data from gene activity, tissue samples, and protein levels to predict drug candidate performance in humans. Benchmarks indicate EVA performs up to twice as well as current AI models in predicting which drug targets will succeed, potentially reducing late-stage failures and accelerating clinical trials for therapies targeting chronic inflammation linked to age-related diseases. The company is releasing an open version of the transcriptomic model for researchers while offering customized commercial applications through partnerships.PharmiWeb.comScienta Lab launches EVA, the first multimodal AI model dedicated to drug discovery and development in immunology and inflammationScienta Lab announced the launch of EVA, the first multimodal AI model purpose-built for drug discovery and development in immunology and inflammation. The model, which integrates over half a million human and murine transcriptomic, histological, and proteomic samples, demonstrates performance gains of up to two-fold compared to current industry standards across 40 benchmarked use cases. The company, founded in Paris in 2021 and selected for the EIC Accelerator program in 2025, aims to help biopharmaceutical teams make earlier, more informed decisions to reduce late-stage clinical failures and accelerate patient access to therapies.GlobeNewswireOSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision ImmunotherapyOSE Immunotherapeutics and Scienta Lab announced a strategic partnership to use Scienta Lab's AI platform EVA for modeling inflammatory diseases and identifying predictive biomarkers for immunotherapies. The collaboration aims to stratify patients by immune-inflammatory subtypes and accelerate development of tailored treatments.HIT ConsultantOSE Immunotherapeutics & Scienta Lab Partner to Advance AI-Driven Drug DiscoveryOSE Immunotherapeutics and Scienta Lab are partnering to use Scienta Lab's AI platform EVA to identify predictive biomarkers for immunotherapies. The collaboration aims to develop tailored immunotherapies and improve outcomes for patients with immune-mediated inflammatory diseases.GlobeNewswireOSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision ImmunotherapyOSE Immunotherapeutics and Scienta Lab announced a strategic partnership to use Scienta Lab's AI platform EVA for modeling inflammatory diseases and identifying predictive biomarkers for immunotherapies. The collaboration aims to stratify patients by immune-inflammatory subtypes and accelerate development of tailored treatments.